{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:57Z","timestamp":1789387617340,"version":"build-2803163510"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can follow a relapsing course, yet evidence for effective maintenance therapy remains limited. Interleukin-6 receptor (IL-6R) inhibition has emerged as a potential relapse-prevention strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of tocilizumab and satralizumab in patients with MOGAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and random-effects proportional meta-analysis conducted in accordance with PRISMA 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Scopus, Web of Science, and Google Scholar were searched from inception through 14 July 2026. Eligible studies reported outcomes in patients with MOGAD treated with an IL-6R inhibitor. The primary outcome was the proportion remaining relapse-free during treatment. Secondary outcomes included annualized relapse rate (ARR), disability, MRI activity, and infectious adverse events. Proportions were pooled using DerSimonian\u2013Laird random-effects models, and study quality was assessed using the Newcastle\u2013Ottawa Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six observational studies comprising 182 treated patients were included. The pooled relapse-free proportion was\n                      <jats:bold>85.0% (95% CI, 78.7%\u201389.6%; I<\/jats:bold>\n                      <jats:sup>\n                        <jats:bold>2<\/jats:bold>\n                      <\/jats:sup>\n                      <jats:bold>=0%)<\/jats:bold>\n                      . ARR decreased consistently across studies, while disability generally stabilized or improved and MRI inflammatory activity decreased or remained stable where reported. Three studies involving 142 patients contributed safety data, with a pooled infectious adverse-event proportion of\n                      <jats:bold>28.0% (95% CI, 21.1%\u201336.0%; I<\/jats:bold>\n                      <jats:sup>\n                        <jats:bold>2<\/jats:bold>\n                      <\/jats:sup>\n                      <jats:bold>=0%)<\/jats:bold>\n                      . Four studies were rated high quality and two moderate quality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-6R inhibition was associated with substantial relapse control in selected patients with MOGAD, supporting its potential role as a maintenance therapy. However, the evidence remains limited by observational designs, heterogeneous treatment regimens and follow-up, concomitant therapies, and the influence of one large cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261490506","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:50:27Z","timestamp":1789145427000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of interleukin-6 receptor inhibitors in myelin oligodendrocyte glycoprotein antibody\u2013associated disease (MOGAD): A systematic review and meta-analysis"],"prefix":"10.1177","volume":"19","author":[{"given":"Aasim","family":"Ali","sequence":"first","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shahid","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad Ullah","family":"Ansari","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maleeha","family":"Rauf","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameen","family":"Sarfraz","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anza","family":"Amjad","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad Yousaf","family":"Masood","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Ali","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Saleem","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asad","family":"Shabbir","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Talha","family":"Shabbir","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armaghana","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Allied Hospital Faisalabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7424-6327","authenticated-orcid":false,"given":"Mukesh Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Dhankuta District Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.041"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10026-y"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000766"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.06.009"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578781"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-90887-0.00015-8"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2291"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510379247"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0717-1"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241306685"},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"e000049","DOI":"10.1212\/WN9.0000000000000049","article-title":"Long-term treatment with interleukin-6 receptor inhibitor tocilizumab in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"2","author":"Capecchi F","year":"2026","unstructured":"Capecchi F, Graure M, Yasaroglu S, et al. Long-term treatment with interleukin-6 receptor inhibitor tocilizumab in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Open Access 2026; 2: e000049. https:\/\/doi.org\/10.1212\/WN9.0000000000000049","journal-title":"Neurol Open Access"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251396421"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30392-6"},{"key":"e_1_3_6_24_2","first-page":"e262220","article-title":"Interleukin 6 receptor blockade for relapse prevention in myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Vilaseca A","year":"2026","unstructured":"Vilaseca A, Bilodeau PA, Gakis G, et al. Interleukin 6 receptor blockade for relapse prevention in myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2026: e262220, Published online July 13. https:\/\/doi.org\/10.1001\/jamaneurol.2026.2220","journal-title":"JAMA Neurol"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42780"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106871"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0489"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261490506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261490506","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261490506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:51:52Z","timestamp":1789386712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261490506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["10.1177\/17562864261490506"],"URL":"https:\/\/doi.org\/10.1177\/17562864261490506","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"17562864261490506"}}